| |
|
|
|
|
|
|
|
|
1. |
Record Nr. |
UNINA9910502658703321 |
|
|
Autore |
Sommermeyer Henning |
|
|
Titolo |
Clostridioides Difficile : infections, risk factors, prevention and treatment / / Henning Sommermeyer, Jacek Pia̜tek |
|
|
|
|
|
|
|
Pubbl/distr/stampa |
|
|
Cham, Switzerland : , : Springer, , [2021] |
|
©2021 |
|
|
|
|
|
|
|
|
|
ISBN |
|
|
|
|
|
|
Descrizione fisica |
|
1 online resource (96 pages) |
|
|
|
|
|
|
Disciplina |
|
|
|
|
|
|
Soggetti |
|
Clostridium difficile |
Clostridi |
Llibres electrònics |
|
|
|
|
|
|
|
|
Lingua di pubblicazione |
|
|
|
|
|
|
Formato |
Materiale a stampa |
|
|
|
|
|
Livello bibliografico |
Monografia |
|
|
|
|
|
Nota di contenuto |
|
Intro -- Foreword -- Preface -- Acknowledgments -- Contents -- About the Authors -- Abbreviations -- List of Figures -- List of Tables -- 1: Introduction -- 2: Microbiology -- 2.1 Taxonomy -- 2.2 Genome -- 2.3 Epigenome -- 2.4 Life Cycle of C. difficile During Infection -- 2.4.1 Spore -- 2.4.1.1 Spore Core -- 2.4.1.2 Inner Membrane -- 2.4.1.3 Germ Cell Wall -- 2.4.1.4 Cortex -- 2.4.1.5 Outer Membrane -- 2.4.1.6 Coat and Exosporium -- 2.4.2 Germination -- 2.4.2.1 Germinosome Model -- 2.4.2.2 Lock-and-Key Model -- 2.4.3 Sporulation -- References -- 3: Pathophysiology of C. difficile -- 3.1 Toxins TcdA and TcdB -- 3.2 Genetics of TcdA and TcdB -- 3.3 Pathogenicity Locus -- 3.4 Toxinotypes of C. difficile Isolates -- 3.5 Environmental Signals Regulating Toxin Expression -- 3.6 Mechanism of Action and Functional Domains of TcdA and TcdB -- 3.7 Cell Surface Receptors for TcdA and TcdB -- 3.8 Receptor-Mediated Endocytosis and Membrane Translocation -- 3.9 Modification of Small GTPase Proteins as Host Cell Targets of TcdA and TcdB -- 3.10 Influence of TcdA and TcdB on Cell Physiology -- 3.11 Impact on Cell Morphology -- 3.12 Impact on Small GTPase Signaling Pathways -- 3.13 Role of TcdA and TcdB in Disease -- 3.14 Other Toxins Produced by C. difficile -- 3.15 Toxin Profiles of Clinical Isolates -- References -- 4: Epidemiology -- 4.1 Historical Perspective -- 4.2 Hospital- |
|
|
|
|
|
|
|
|
|
|
and Community-Acquired CDI -- 4.3 Hypervirulent C. difficile Strain Ribotype 027 (NAP1/BI) -- 4.4 Other Strains of C. difficile -- 4.5 Dual Strain Infections -- 4.6 CDI in Children -- 4.7 Recurrent CDI -- References -- 5: Risk Factors for CDI -- 5.1 Exposure to Healthcare Institutions -- 5.2 Antibiotics -- 5.3 Proton Pump Inhibitors -- 5.4 Advanced Age as Risk Factor for CDI -- 5.5 Cancer Therapy as Risk Factor for CDI. |
5.6 Other Risk Factors for CDI -- 5.7 Risk Factors for Community-Acquired CDI -- 5.8 Risk Factors for Recurrent CDI -- 5.9 CDI Risk Factors in Children -- References -- 6: Diagnosis of CDI -- References -- 7: Clinical Picture of CDI -- 7.1 From Asymptomatic Carriers to Life-Threatening Presentations -- 7.2 Pseudomembranous Colitis -- References -- 8: Treatment of CDI -- 8.1 Antibiotics-Based Therapy -- 8.1.1 Antibiotics Used for Treatment of CDI -- 8.1.2 AB-Treatment of an Initial, Non-severe CDI Episode in Adults -- 8.1.3 AB-Treatment of a Fulminant Episode of CDI in Adults -- 8.1.4 AB-Treatment of a First or Multiple Recurrence of CDI in Adults -- 8.1.5 AB-Treatment of Non-severe Initial or First Recurrent CDI in Children -- 8.1.6 AB-Treatment of an Initial Episode of Severe CDI in Children -- 8.1.7 AB-Treatment of Second or Greater Episode of Recurrent CDI in Children -- 8.2 Fecal Microbiota Transplantation as Treatment for CDI -- 8.3 Probiotics and Synbiotics as Treatment for CDI -- 8.4 Surgical Treatment of Complicated CDI -- References -- 9: Prophylaxis of CDI -- 9.1 Probiotics and Synbiotics for Prophylaxis of CDI -- 9.2 Bezlotoxumab for the Prevention of Recurrent CDI -- References -- 10: Summary and Discussion -- 10.1 Spores -- 10.2 Pathophysiology -- 10.3 Epidemiology -- 10.4 Risk Factors -- 10.5 Diagnosis -- 10.6 Clinical Picture -- 10.7 Treatment -- 10.8 Prophylaxis -- 10.9 General Outlook. |
|
|
|
|
|
| |